Search

EHA-TSH Hematology Tutorial

EHA is joining the Turkish Society of Hematology (TSH) to organize the EHA-TSH Hematology Tutorial on T Cell Lymphomas. Date: June 29-30, 2024
Location: Ankara, Türkiye
Format: In-Person

Target audienceHematology fellows from Türkiye.

EHA Research Conference 2025

Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson,
Özgen Deniz, Kimberley Stegmaier, and Nina Cabezas-Wallscheid

Registration is now open

EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…

EHA Bilateral Collaborative Grant

The call for applications will close on October 15, 2024, at 15:00 (CEST).

EHA-HKSH Hematology Tutorial

EHA is joining the Hong Kong Society of Hematology (HKSH) to organize the EHA-HKSH Hematology Tutorial on Lymphoid Malignancies.

Non-EHA Funding Opportunities

Here you will find other interesting funding opportunities for European researchers in hematology. If you are interested in adding additional opportunities to this page, please contact research@ehaweb. org.

EHA Kick-off Grants

The call for applications will close on October 1, 2024, at 15:00 (CEST). Apply now

The EHA Kick-off Grant is a one-year grant intended to support basic and translational early career researchers in hematology.

EHA-KCS Hematology Tutorial

EHA is joining the Kazakhstan Cancer Society (KCS) to organize the EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies.

EHA-SPH joint membership

Save up to €50 by becoming a joint member of EHA and the Sociedade Portuguesa de Hematologia. We've joined forces with the Sociedade Portuguesa de Hematologia (SPH) to offer a special joint membership deal during 2024.

EHA-SPSHTM joint membership

Save up to €75 by becoming a joint member of EHA and the Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

Dec 13 2023

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).